By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.
Innovative mental health medicines
Our Target
PHARMACEUTICAL: KRN-101
A Psilocybin-based medicine derived from mycelium extracts, manufactured with our patented bioreactor technology
- Natural
- Standardized
- Safe
- Effective
LEAD INDICATION: CANCER-RELATED ANXIETY
- No current treatment - unmet need
- Fast expansion to addiction and PTSD
- Access to early revenue in UK (through Real World Evidence)
- Estimated revenue per patient $7,500
- Patients currently suffering:
- UK = 1 million
- USA = 6 million
- EU = 7 million
Stock & Sector Performance
ABRT vs. Peers
Stoic Report (Oct 22)
Psychedelics Index June
October 2022
Key Assets
Value created from $4.7 million Series A raise
Canada
Portugal
UK
Australia
Accomplished Management Team
Previous experience...
Next Steps:
Value Milestones
-
Pre-Clinical Studies Completed (Q4 2022)
KRN-101 ready for regulatory submissions and available for licensing -
In-Human Study (Q2/Q3 2023)
32 Patients
43.5% rebate of all costs from Australian Govenment -
RWE Clinical Trial Initiation (Q4 2023)
~250 patients
Cancer-related Distress
Phase 2b (MHRA) -
FDA Application (Q4 2023)
Phase 2b (FDA)
Submissions for further trials in the US market
Clinical development programme with comparable valuations
Invest in a breakthrough technology for mental health
Reserve your shares…
Contact us directly for discounted shares
CANADIAN SECURITIES EXCHANGE RULES HAVE CHANGED
Click here to access our investor documents